DIANT® Pharma Inc launches LARU Discovery, a highly innovative nanoparticle research system

DIANT’s game changing approach to the continuous processing of nanoparticles has becomethe industry’s benchmark. Featuring patented turbulent jet technology, the DIANT® LARUDiscovery enables lowest volume research test runs for multi-mode specification andoptimization of nanoparticle processing

August 2024
DIANT Pharma Inc. is well known for their continuous nanoparticle and LNP
processing systems, which range from R&D to commercial scale with the highest
yield and state-of-the-art process controls. These novel and linear scalable
processing systems find wide use within the industry and regulators alike, in multiple
key applications.


Addressing the needs of research applications, DIANT has introduced the LARU
Discovery, a low-volume system tailored for the research requirements of both
industry and academia.

“In close collaboration with our customers, understanding their evolving needs, we
identified the necessity to downscale our research unit, LARU, to a smaller volume
level while maintaining scalability across our extensive product line,” explains Dr.
Antonio Costa, CEO of DIANT Pharma Inc. “Our innovation efforts have given rise to
the LARU Discovery, a low-volume processing system. It incorporates the same highly
efficient and precise turbulent mixing technology but at a reduced flow rate and hold-
up volume. The positive feedback from our customers and stakeholders indicates
that we have effectively met their demands once again.“

The DIANT LARU Discovery system is compact with a low footprint need, can be
utilized at minimum collection volumes and has the flexibility to process and test
multiple fluid and mixing modalities. It is ideal to run feasibility studies and
determine the optimal fluid and operating parameter compositions at lowest hold-up
volumes. The LARU Discovery is fully scalable to DIANT’s large volume processing
system like the CGMP compliant LiFT system.

DIANT Pharma Inc
DIANT® Pharma was formed in 2019. Our groundbreaking technology emerged from
years of rigorous research at the University of Connecticut, resulting in differentiated,
innovative continuous processing technologies for nanoparticle-based therapeutics
and vaccines.

DIANT PHARMA INC.
130 Utopia Rd.
Manchester CT, 06042
USA
info@diantpharma.com
www.diantpharma.com